Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor. It is primarily used to treat inflammatory conditions such as rheumatoid arthritis and juvenile idiopathic arthritis. In recent times, it has gained attention for its potential role in treating severe cases of COVID-19.
